Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1994-01-24
1996-01-30
Budens, Robert D.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241421, 4241471, 4241501, 4241531, 435 7021, 4351722, 43524027, 5303873, 53038815, 5303883, 5303884, A61K 39395, A61K 3940, A61K 3942
Patent
active
054878900
ABSTRACT:
Mammalian red blood cells are used to safely and rapidly neutralize and/or clear antigens or immunogens from the circulatory system by binding to the RBC a monoclonal antibody specific for a receptor (CR1) on the RBC, which monoclonal antibody is chemically bound to a second Mab specific for the antigen to be cleared from the circulatory system. These chemically cross-linked monoclonal antibody heteropolymers may be injected directly into the patient's circulatory system. Alternatively, red blood cells, extracted from the patient or provided by a suitable donor, are bound to the Mab complex and returned to the system.
REFERENCES:
patent: 4433059 (1984-02-01), Chang et al.
Edberg et al., "Quantitative Andyes Of The Binding Of Soluble Complement Fixing Antibody/dsDNA Immune Complexes To CR1 On Human Blood Cells" J. Immunol. 139(11):3739-3747, Dec. 1, 1987.
Titus et al., "Human K/Natural Killer Cells Targeted With Hetero-Cross-Linker Antibodies Specifically Lyse Tumor Cells In Vitro And Prevent Tumor Growth In Vivo," J. Immunol. 139(9):3153-3158, Nov. 1, 1987.
Karporsky et al, "Production Of Target Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fc.sub..lambda. Receptor Antibodies," J. Exp. Med. 160:1686-1701, Dec., 1984.
Taylor et al., "In Vivo Binding And Clearance Of Circulating Antigen By Bispecific Heteropolymer-Medical Binding To Primate Erythrocyte Complement Receptor," J. Immunol. 148(8):2462-2468, Apr. 15, 1992.
Kimberly et al., "In Vivo Handling Of Soluble Complement Fixing Ab/dsDNA Immune Complexes In Chimpanzees," J. Clin. Invest. 84:962-970, Sep. 1989.
Reist et al., "Antigens Pre-Bound To The Primate Erythrocyte Complement Receptor Via Cross-linked Bispecific Monoclonal Antibody Heteropolymers Are Rapidly Cleared From The Circulatory," Eur. J. Immunol. 23:3021-3027, 1993.
Labuguen Ronald
Reist Craig
Sutherland William M.
Taylor Ronald P.
Webb Donna
Budens Robert D.
University of Virginia Patent Foundation
LandOfFree
Mammalian primate erythrocyte bound heteropolymerized monoclonal does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mammalian primate erythrocyte bound heteropolymerized monoclonal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mammalian primate erythrocyte bound heteropolymerized monoclonal will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-155763